Search Results

1 - 10 of 438 items :

  • "colorectal cancer" x
Clear All
The Role of Smoking in the Development of Colorectal Cancer

Risc of Colorectal Cancer: A Meta-analysis of Prospctive Cohort Studies. Clin Gastroenterol Hepatol. 2009;7:682-688.e1-5. doi: 10.1016/j.cgh.2009.02.016. 5. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risc of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:725-731. 6. Cleary SP, Cotterchio M, Shi E, Gallinger S, Harper P. Cigarette Smoking, Genetic Variants in Carcinogen-metabolizing Enzymes, and Colorectal Cancer Risc. Am J Epidemiol. 2010;172:1000-1014. doi: 10.1093/aje/kwq245. 7

Open access
Microsatellite instability in colorectal cancer

References Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet 2005; 365 : 153-65. Primic-Žakelj M, Zadnik V, Žagar T, Zakotnik B. Survival of cancer patients, diagnosed in 1991-2005 in Slovenia. Ljubljana: Institute of Oncology Ljubljana, Cancer Registry of Republic of Slovenia; 2009. Cancer incidence in Slovenia 2007. Ljubljana: Institute of Oncology Ljubljana, Cancer Registry of Republic of Slovenia; 2010. Velenik V

Open access
The Association of Cholelithiasis and Colorectal Cancer

bile acids after cholecystectomy. Gut. 1978;19(7):640-9. 10. Hartz A, He T, Ross JJ. Risk factors for colon cancer in 150,912 postmenopausal women. Cancer Causes Control. 2012;23(10):1599-605. 11. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology. 2010;138(6):2029-2043. 12. Huxley RR, Ansary-Moghaddam A, Clifton P, et al. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer. 2009

Open access
Post-treatment surveillance in colorectal cancer

for identifying resectable recurrence and success rates after resection. Ann Intern Med 1998; 129 : 27-35. Velenik V. Locally recurrent rectal cancer: treatment options. Radiol Oncol 2009; 43 : 144-51. Cali RL, Pitsch RM, Thorson AG, Watson P, Tapia P, Blatchford GJ, et al. Cumulative incidence of metachronous colorectal cancer. Dis Colon Rectum 1993; 36 : 388-93. Enblad P, Adami HO, Glimelius B, Krusemo U, Pahlman L. The risk of subsequent primary malignant diseases after cancers

Open access
Distant Liver Metastases as a Major Factor Influencing Survival in Patients with Colorectal Cancer

REFERENCES 1. Duraker Н, Çaynak Z, Hot S. The impact of primary tumor resection on overall survival in patients with colorectal carcinoma and unresectable distant metastases: A prospective cohort study. International Journal of Surgery 2014;12(7):737-41. 2. Dimitrova N. Colon (C18,ICD10) In: Dimitrova N, Vukov M, Valerianova Z. Cancer incidence in Bulgaria 2011. Volume XXII. Paradigma”2013”;2013:56. 3. Mantke R, Schmidt U, Wolff S, et al. Incidence of synchronous liver metastases in patients with colorectal cancer in relationship to

Open access
Clinico-Pathological Presentation of Colorectal Cancer Seen in Lagos State University Teaching Hospital

References 1. Naader SB, Archampong EQ. Cancer of the colon and rectum in Ghana:A five year prospective study of Ghana Medical School, Accra. BJ of Surg. 1994;81:456-459. 2. Adesanya AA, Darocha-Afodu JT. Colorectal Cancer in Lagos; A critical review of 100 cases. The Nig Postgraduate Med Journal. 2000;7(3). 3. James AM, Leonard LG. Colon and Rectum;Principle and Practice of Radiation Oncology; 3rd ed. Lippincott-Raven Publisher, 1997:1489-1506. 4. Elias D, Karan S, Richard L, Martin JH

Open access
Analysis of the role of RAS Family Mutations in Metastatic Colorectal Cancer (mCRC): Current Treatment Practice

References [1] (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337. [2] Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634. [3] Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765. [4] Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R

Open access
Association of Helicobacter pylori with colorectal cancer development

:163-7. 5. Breuer-Katschinski B, Nemes K, Marr A, Rump B, Leiendecker B, Breuer N, Goebell H. Helicobacter pylori and the risk of colonic adenomas. Colorectal Adenoma Study Group. Digestion. 1999; 60:210-5. 6. Fireman Z, Trost L, Kopelman Y, Segal A, Sternberg A. Helicobacter pylori: seroprevalence and colorectal cancer. Isr Med Assoc J. 2000; 2:6-9. 7. Shmuely H, Passaro D, Figer A, Niv Y, Pitlik S, Samra Z, et al. Relationship between Helicobacter pylori CagA status and colorectal cancer. Am J Gastroenterol. 2001; 96

Open access
Fecal Calprotectin Dosage Value as A Diagnostic and Postoperative Marker in Diabetic Patients with Colorectal Cancer

References 1. Ferlay J, Soerjomataram I, Ervik M at al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from:, accessed on 05.11.2014 2. Hart AR, Wicks AC, Mayberry JF. Colorectal cancer screening in asymptomatic populations. Gut 36: 590-598, 1995. 3. Røseth AG, Kristinsson J, Fagerhol MK at al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer

Open access
Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience

Introduction As with many cancers, metastatic colorectal cancer (mCRC) is mainly a disease of elderly population. However, geriatric population is underrepresented in clinical trials. The median age at diagnosis for patients with CRC is 72 years, while the median age of patients in clinical trials is 63 years. 1 In Slovenia, 44% of colorectal cancer cases were diagnosed in people aged 70 years and over. 2 Age together with performance status and comorbidities is one of the most important factors when deciding on treatment regimen. 3 Studies show that

Open access